Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 285

The DOI matches its Crossref record.

A well‐tolerated grass pollen‐specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

Open access
Drachenberg, K. J., Wheeler, A. W., Stuebner, P., Horak, F.·2001·Allergy

Abstract

Background: We present data showing that a Th1‐inducing adjuvant can reduce the number of injections required for allergy vaccination. Allergy vaccination is the only treatment for type 1 hypersensitivity that can alter the underlying disease process. A switch of specific T‐cell activity from Th2>Th1 to Th1>Th2 is believed to be an important change seen after long‐term vaccination therapy. An immunologic adjuvant that enhances such a switch could be used to reduce the number of injections required. This would improve compliance with the treatment and provide pharmacoeconomic advantages. Such an adjuvant is 3‐deacylated monophosphoryl lipid A (MPL® adjuvant, Corixa). Methods: A multicentre, placebo‐controlled, randomized, double‐blind clinical study was performed with a new standardized allergy vaccine comprising a tyrosine‐adsorbed glutaraldehyde‐modified grass pollen extract containing MPL® adjuvant. Four subcutaneous injections of the active product were given preseasonally to 81 grass pollen‐sensitive subjects, and 60 received placebo injections (tyrosine alone). Diary cards were used to record symptoms and medication taken during approximately 30 days of the grass pollen season. Results: There was a statistical advantage in favour of the active treatment for nasal (P=0.016) and ocular (P=0.003) symptoms and combined symptom and medication scores (P=0.013). Titrated skin prick testing revealed a significant reduction of skin sensitivity in the active group compared to placebo (P=0.04). Grass‐pollen‐specific IgG antibody was raised by active treatment (P<0.01). A rise in IgE antibody was seen in the placebo group during the season (P<0.01). The first year's treatment rise of IgE was not seen in the active group, and no rise occurred during the pollen season. More local adverse events were seen in the active group. There was no difference in generalized adverse events. Conclusions: A new, well‐tolerated allergy vaccine, incorporating a Th1‐inducing adjuvant, MPL®, was efficacious and after only four preseasonal injections produced antibody changes normally associated with long injection schedules. This may encourage wider application of allergy vaccination. The vaccine is now available in a number of countries as Pollinex Quattro®.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1034/j.1398-9995.2001.056006498.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 285

Metadata

Authors
Drachenberg, K. J., Wheeler, A. W., Stuebner, P., & Horak, F.
Venue
Allergy
Publisher
Wiley
Published
2001-06
Volume
56
Issue
6
Pages
498-505
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
OpenAlex
W1964354442
Cited by
285
References
0
FWCI
4.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A well‐tolerated grass pollen‐specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. https://app.cochat.ai/papers/10.1034/j.1398-9995.2001.056006498.x
The paper
Drachenberg, K. J., Wheeler, A. W., Stuebner, P., & Horak, F. (2001). A well‐tolerated grass pollen‐specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. https://doi.org/10.1034/j.1398-9995.2001.056006498.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.